Navigation Links
PAREXEL Chief Operating Officer Dr. Mark A. Goldberg Receives Special Recognition Award
Date:4/23/2012

BOSTON, April 23, 2012 /PRNewswire/ -- PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services organization, today announced that its Chief Operating Officer (COO), Mark A. Goldberg, M.D., was honored by the Academy of Physicians in Clinical Research (APCR). Dr. Goldberg was recognized for his contributions to the advancement of clinical research during the awards ceremony and reception at the Association of Clinical Research Professionals (ACRP) 2012 Global Conference & Exhibition in Houston, Texas on April 15, 2012.

Dr. Goldberg was honored with this year's APCR Special Recognition Award for his embodiment of APCR's values and for the advancement of clinical research by combining his medical knowledge and development expertise with the application of information technology.  For nearly two decades, he has pursued a vision to help biopharmaceutical companies leverage information technology to improve decision making and bring efficiencies to clinical development.  COO since 2008, Dr. Goldberg has been an asset to PAREXEL's executive management team for 15 years. In 2000, he was involved in establishing Perceptive Informatics, PAREXEL's technology subsidiary and a leading eClinical solutions provider, to deliver advanced technology solutions.  Prior to being appointed COO, Dr. Goldberg led strong performance in Clinical Research Services, PAREXEL's largest business segment, and oversaw the geographic expansion of PAREXEL's services, including the extension of capabilities in the Asia-Pacific region.

"I am honored by this recognition from the APCR, the leading professional organization dedicated to supporting and addressing the unique issues and challenges of physicians in clinical research," said Dr. Goldberg. "This award is a testament to PAREXEL's longstanding vision of leveraging information technology to improve efficiency and effectiveness throughout the clinical development process." 

Prior to PAREXEL, Dr. Goldberg served as president and director of WorldCare, Inc., a telehealth spin off from Massachusetts General Hospital.  He holds a degree in computer science and engineering from the Massachusetts Institute of Technology, and earned his medical degree from the University of Massachusetts Medical School.

The APCR Special Recognition Award is presented annually to an individual who has demonstrated exceptional performance, achievement and sustained service toward the goals of the APCR, and has made significant contributions to the betterment of the APCR overall. Past recipients include: Senator Edward Kennedy in 2008, Robert J. Levine in 2009, Robert M. Califf in 2010 and Carl Peck in 2011. More information about the APCR Awards can be found at www.acrp2012.org.

About PAREXEL InternationalPAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement.  Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process.  Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 52 countries around the world, and has approximately 11,300 employees. For more information about PAREXEL International visit www.PAREXEL.com.

This release contains "forward-looking" statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand.
For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements.  Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "will," "would," "could," "should,"  "targets," and similar expressions are also intended to identify forward-looking statements.  The forward-looking statements in this release involve a number of risks and uncertainties.  The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release.  Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings, including the anticipated additional restructuring charges of approximately $2.0 million in the third quarter of Fiscal Year 2012; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug,  medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks.
Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the quarter ended December 31, 2011 as filed with the SEC on February 9, 2012, which "Risk Factors" discussion is incorporated by reference in this press release.  The Company specifically disclaims any obligation to update these forward-looking statements in the future.  These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.Contacts:Georgina Cattaway, Director Marketing

Kim Leadley/Gene Carozza PAREXEL International

PAN CommunicationsTel: +44 1895 614530

Tel: + 617-502-4300Email: Georgina.Cattaway@PAREXEL.com

Email: PAREXEL@pancomm.com


'/>"/>

SOURCE PAREXEL International Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. PAREXEL Announces Date of Third Quarter Fiscal Year 2012 Earnings Release and Conference Call
2. PAREXEL to Address New Regulatory Guidelines and Data Standards at DIA EuroMeeting
3. PAREXEL Global Survey Results Identify Top Concerns of Biopharma Industry in Achieving Commercial Success
4. PAREXEL International to Present at Barclays Capital Healthcare Conference
5. PAREXEL International to Present at Cowen Healthcare Conference and Raymond James Investors Conference
6. PAREXEL to Address Innovative Approaches to Late Stage Development at Summit for Clinical Ops Executives
7. PAREXEL Expands Alliance Network to Support Early Phase Patient Studies, Establishes Collaboration With University Hospitals Bristol NHS Foundation Trust
8. PAREXEL Announces Date of Second Quarter Fiscal Year 2012 Earnings Release and Conference Call
9. PAREXEL Strengthens Late Phase and Observational Research Capabilities With Expert Team to Help Biopharma Meet Commercialization Goals
10. PAREXEL Advances Early Phase CNS Research Capabilities With Leading Medical Imaging Technology
11. UCB and PAREXEL Sign Strategic Partnership Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... -- Lianluo Smart Limited (Nasdaq: LLIT ... markets and sells medical devices and wearable sleep ... and international markets, recently attended the 2016 Guangdong ... Forum, co-hosted by the Institute of Interventional Cardiology ... Provincial People,s Hospital and Cardiology Department of Guangdong ...
(Date:12/2/2016)... Dec. 1, 2016 The concept of rare diseases ... given to this sector has been taking shape in ... the political aspects and initiatives related to orphan medicinal products ... the level of member states individually. Many member states in ... the space of orphan medicinal products, the result of which ...
(Date:12/2/2016)... Dec. 2, 2016 Allergan plc (NYSE: ... information on its previously announced Accelerated Share Repurchase (ASR) Program. ... ... As previously announced, the Company entered into a ... the Company will repurchase $10 billion of its ordinary shares. ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... December 02, 2016 , ... With the number of pain management programs ... patients must find the one that works for them. When an inventor from Suisun ... that worked and decided to share it with others. , He developed a prototype ...
(Date:12/2/2016)... ... December 02, 2016 , ... Dr. Raffi Hovsepian, a leading ... the 2016 “Guide to America’s Top Plastic Surgeons” for seven consecutive years. The ... education, experience, and professional associations. , One the most frequently honored surgeons ...
(Date:12/2/2016)... ... 2016 , ... Mediaplanet is proud to announce the launch ... innovative treatments, therapeutic technologies, and revolutionized nutrition that are helping patients and physicians ... years in the last 3 decades,” says Dr. Valentine Fuster, a world-renowned cardiologist. ...
(Date:12/2/2016)... ... December 02, 2016 , ... The PAINWeekEnd Regional Conference will ... Spa in Honolulu, offering local frontline clinicians the opportunity to extend their certified ... demand for supplemental training related to pain management has surged dramatically in recent ...
(Date:12/2/2016)... ... December 02, 2016 , ... Sourced from the Isbre Springs beneath the 5,000 ... unmatched natural purity of just 6 ppm TDS (Total Dissolved Solids) in addition to ... been available in several ShopRite and FoodTown stores in NJ and received rave comments ...
Breaking Medicine News(10 mins):